Project Grant K38HL180910
Award Date 9/9/25
Completion Date 8/31/27
Dollars Obligated $106K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Colorado, USA
Similar Awards
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $586,021 to The Medical College of Wisconsin, Inc. to establish patient-reported outcome measures that refine neonatal risk stratification and identify barriers to post-discharge specialty care for preterm infants with bronchopulmonary dysplasia (BPD). The goal is to identify hospital-to-home transition strategies that reduce post-prematurity respiratory...
- This Project Grant award of $497,628.00 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into pulmonary vagal sensory neurons and their role in breathing abnormalities associated with bronchopulmonary dysplasia (BPD) in preterm infants. The research aims to elucidate the dose- and duration-dependent effects of neonatal hyperoxia exposure on breathing control and the functional roles of distinct populations of...
- This federal Project Grant award, funded by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the role of the hedgehog pathway and primary cilia axis in human lung alveologenesis and diseases such as bronchopulmonary dysplasia (BPD). The $156,168 grant awarded to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center will fund a 2-year study examining the cellular and molecular...
- This $721,826 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify molecular mechanisms regulating alveolar matrix fibroblast function and their role in supporting vascular capillary formation. The research is being conducted by Children's Hospital Medical Center in Cincinnati, Ohio to advance the understanding of alveolar septation and septal wall maturation, which is...
- This $166,752 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research at Trustees of Boston University to investigate the signaling mechanisms underlying lung branching morphogenesis. The project aims to combine developmental biology approaches with synthetic biology tools to elucidate the reaction-diffusion patterning that directs the assembly of the elaborate bronchial network in the lung. This work could provide...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA Program 93.837 Cardiovascular Diseases Research) provides $730,070 to the University of Arizona to develop and test a novel class of hybrid polyplex nanoparticles (P22-F1 PBAE/PEI/PEG) that can specifically target and deliver DNA plasmids to lung capillary endothelial cells. The goal is to stimulate lung regeneration and decrease pulmonary hypertension in mouse and rat models of bronchopulmonary dysplasia, a severe...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), will fund a study on the early life predictors of airway-to-lung mismatch, a condition known as dysanapsis. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $753,018 to leverage longitudinal data from 8 diverse birth cohorts to examine the relationship between early-life exposures, such...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $773,868 to Baylor College of Medicine to elucidate the mechanisms regulating inflammation and the role of regulatory T cells (Tregs) in the development of bronchopulmonary dysplasia-associated pulmonary hypertension (BPD-PH). The award aims to use well-established murine models and human biosamples to examine the mechanistic and therapeutic potential of Tregs in...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $166,752 to Boston Medical Center Corporation to develop models of placenta-driven developmental lung injury in human preeclampsia. The 5-year project aims to characterize the influence of human preeclampsia on fetal lung development. Specifically, the research will: 1) Identify preeclampsia-specific placental proteins in the fetal circulation that...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $106,391 to the University of Colorado-Denver to investigate the role of developmental dysanapsis in lung development over the lifespan in an experimental bronchopulmonary dysplasia (BPD) model. The research aims to determine whether intra-amniotic endotoxin causes persistent dysanaptic growth of the airways, distal parenchyma, and vasculature in BPD, and whether these structural changes contribute to impaired lung biomechanics, pulmonary hypertension, and increased susceptibility to postnatal insults. The award period is from Sep 9, 2025 through Aug 31, 2027.
Generated 10/21/25, 6:38 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $106.4k | 9/9/25 |